2. Asia Pacific: In Asia Pacific, China, Japan, and South Korea are the key markets for lipid-lowering drugs. China's market is witnessing rapid growth due to increasing urbanization, changing dietary habits, and rising healthcare expenditure. Japan has a well-established market for lipid-lowering drugs with a high prevalence of cardiovascular diseases. South Korea is also experiencing steady growth in the lipid-lowering drugs market due to the increasing incidence of lifestyle-related diseases.
3. Europe: The lipid-lowering drugs market in Europe is led by the United Kingdom, Germany, and France. These countries have well-developed healthcare infrastructure and high awareness about cardiovascular diseases. The market is characterized by a strong presence of generic drugs and a rising trend towards personalized medicine. The increasing geriatric population in these countries also contributes to the growth of the lipid-lowering drugs market.